Literature DB >> 23552180

Treating older adults with schizophrenia: challenges and opportunities.

Dilip V Jeste1, Jeanne E Maglione.   

Abstract

Schizophrenia affects people of all age groups. Treatment plans for older adults with schizophrenia must consider the effects of age on the course of the illness as well as on the response to antipsychotics and to psychosocial interventions. Positive symptoms of schizophrenia tend to become less severe, substance abuse becomes less common, and mental health functioning often improves. Hospitalizations are more likely to be due to physical problems rather than psychotic relapses. Physical comorbidity is a rule, however, and older age is a risk factor for most side effects of antipsychotics, including metabolic syndrome and movement disorders. We recently reported high rates of adverse events and medication discontinuation along with limited effectiveness of commonly used atypical antipsychotics in older adults. Psychosocial interventions such as cognitive behavioral social skills training are efficacious in improving functioning in older adults with schizophrenia. In formulating treatment plans for this population, a balanced approach combining cautious antipsychotic medication use with psychosocial interventions is recommended. Antipsychotic medications should generally be used in lower doses in older adults. Close monitoring for side effects and effectiveness of the medications and a watchful eye on their risk:benefit ratio are critical. In a minority of patients it may be possible to discontinue medications. Sustained remission of schizophrenia after decades of illness is not rare, especially in persons who receive appropriate treatment and psychosocial support-there can be light at the end of a long tunnel.

Entities:  

Keywords:  aging; antipsychotics; cognition; psychosis; psychosocial treatments; schizophrenia

Mesh:

Substances:

Year:  2013        PMID: 23552180      PMCID: PMC3756792          DOI: 10.1093/schbul/sbt043

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  15 in total

1.  Mobile interventions for severe mental illness: design and preliminary data from three approaches.

Authors:  Colin A Depp; Brent Mausbach; Eric Granholm; Veronica Cardenas; Dror Ben-Zeev; Thomas L Patterson; Barry D Lebowitz; Dilip V Jeste
Journal:  J Nerv Ment Dis       Date:  2010-10       Impact factor: 2.254

2.  Functional adaptation skills training (FAST): a randomized trial of a psychosocial intervention for middle-aged and older patients with chronic psychotic disorders.

Authors:  Thomas L Patterson; Brent T Mausbach; Christine McKibbin; Sherry Goldman; Jesus Bucardo; Dilip V Jeste
Journal:  Schizophr Res       Date:  2006-06-30       Impact factor: 4.939

3.  Randomized trial of social rehabilitation and integrated health care for older people with severe mental illness.

Authors:  Kim T Mueser; Sarah I Pratt; Stephen J Bartels; Karin Swain; Brent Forester; Corinne Cather; James Feldman
Journal:  J Consult Clin Psychol       Date:  2010-08

Review 4.  Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia.

Authors:  Dilip V Jeste; Owen M Wolkowitz; Barton W Palmer
Journal:  Schizophr Bull       Date:  2011-05       Impact factor: 9.306

5.  11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

Authors:  Jari Tiihonen; Jouko Lönnqvist; Kristian Wahlbeck; Timo Klaukka; Leo Niskanen; Antti Tanskanen; Jari Haukka
Journal:  Lancet       Date:  2009-08-22       Impact factor: 79.321

6.  Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.

Authors:  Hua Jin; Pei-an Betty Shih; Shahrokh Golshan; Sunder Mudaliar; Robert Henry; Danielle K Glorioso; Stephan Arndt; Helena C Kraemer; Dilip V Jeste
Journal:  J Clin Psychiatry       Date:  2012-11-27       Impact factor: 4.384

7.  Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.

Authors:  Hiroyuki Uchida; Shitij Kapur; Benoit H Mulsant; Ariel Graff-Guerrero; Bruce G Pollock; David C Mamo
Journal:  Am J Geriatr Psychiatry       Date:  2009-03       Impact factor: 4.105

Review 8.  A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?

Authors:  Sukanta Saha; David Chant; John McGrath
Journal:  Arch Gen Psychiatry       Date:  2007-10

9.  Randomized controlled trial of cognitive behavioral social skills training for older people with schizophrenia: 12-month follow-up.

Authors:  Eric Granholm; John R McQuaid; Fauzia Simjee McClure; Peter C Link; Dimitri Perivoliotis; Jennifer D Gottlieb; Thomas L Patterson; Dilip V Jeste
Journal:  J Clin Psychiatry       Date:  2007-05       Impact factor: 4.384

10.  Physical and mental health-related quality of life among older people with schizophrenia.

Authors:  David P Folsom; Colin Depp; Barton W Palmer; Brent T Mausbach; Shahrokh Golshan; Ian Fellows; Veronica Cardenas; Thomas L Patterson; Helena C Kraemer; Dilip V Jeste
Journal:  Schizophr Res       Date:  2009-01-24       Impact factor: 4.939

View more
  21 in total

1.  Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.

Authors:  Eric J Lenze; Benoit H Mulsant; Daniel M Blumberger; Jordan F Karp; John W Newcomer; Stewart J Anderson; Mary Amanda Dew; Meryl A Butters; Jacqueline A Stack; Amy E Begley; Charles F Reynolds
Journal:  Lancet       Date:  2015-09-27       Impact factor: 79.321

2.  [Schizophrenia spectrum disorders in elderly patients : Analysis of reasons for admission to a department of geriatric psychiatry].

Authors:  C Jagsch; G Dietmaier; M Jagsch; R E Roller
Journal:  Z Gerontol Geriatr       Date:  2016-07-19       Impact factor: 1.281

3.  Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study.

Authors:  Parita Shah; Yusuke Iwata; Eric E Brown; Julia Kim; Marcos Sanches; Hiroyoshi Takeuchi; Shinichiro Nakajima; Margaret Hahn; Gary Remington; Philip Gerretsen; Ariel Graff-Guerrero
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-08-19       Impact factor: 5.270

4.  Preparing Long-Term Care Staff to Meet the Needs of Aging Persons With Serious Mental Illness.

Authors:  Anjana Muralidharan; Whitney L Mills; Denise R Evans; Daryl Fujii; Victor Molinari
Journal:  J Am Med Dir Assoc       Date:  2019-05-02       Impact factor: 4.669

5.  Assessing Social Connectedness Among Persons with Schizophrenia: Psychometric Evaluation of the Perceived Social Connectedness Scale.

Authors:  Scott E Wilks; Mary E Heintz; Catherine M Lemieux; Xi Du
Journal:  J Behav Health Serv Res       Date:  2020-01       Impact factor: 1.505

6.  Dopamine D₂/₃ receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [¹¹C]-raclopride PET study.

Authors:  Shinichiro Nakajima; Fernando Caravaggio; David C Mamo; Benoit H Mulsant; Jun Ku Chung; Eric Plitman; Yusuke Iwata; Philip Gerretsen; Hiroyuki Uchida; Takefumi Suzuki; Wanna Mar; Alan A Wilson; Sylvain Houle; Ariel Graff-Guerrero
Journal:  Schizophr Res       Date:  2015-03-08       Impact factor: 4.939

7.  Altered Glutamate and Regional Cerebral Blood Flow Levels in Schizophrenia: A 1H-MRS and pCASL study.

Authors:  S Andrea Wijtenburg; Susan N Wright; Stephanie A Korenic; Frank E Gaston; Nkemdilim Ndubuizu; Joshua Chiappelli; Robert P McMahon; Hongji Chen; Anya Savransky; Xiaoming Du; Danny J J Wang; Peter Kochunov; L Elliot Hong; Laura M Rowland
Journal:  Neuropsychopharmacology       Date:  2016-08-26       Impact factor: 7.853

Review 8.  Use of atypical antipsychotics in the elderly: a clinical review.

Authors:  Pietro Gareri; Cristina Segura-García; Valeria Graziella Laura Manfredi; Antonella Bruni; Paola Ciambrone; Gregorio Cerminara; Giovambattista De Sarro; Pasquale De Fazio
Journal:  Clin Interv Aging       Date:  2014-08-16       Impact factor: 4.458

9.  [Clinical diagnosis and drug therapy of elderly patients with schizophrenia : A restrospective analysis of data in a department of old age psychiatry].

Authors:  Christian Jagsch; Gabriele Dietmaier; Maximilian Jagsch; Martin Kurz
Journal:  Neuropsychiatr       Date:  2016-06-13

10.  Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics.

Authors:  Natalie Matosin; Francesca Fernandez-Enright; Elisabeth Frank; Chao Deng; Jenny Wong; Xu-Feng Huang; Kelly A Newell
Journal:  J Psychiatry Neurosci       Date:  2014-11       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.